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Introduction: The key feature of the newborn is its fast age-dependent matu-
ration, resulting in extensive variability in pharmacokinetics and -dynamics,
further aggravated by newly emerging covariates like treatment modalities,
environmental issues or pharmacogenetics. This makes clinical research in
neonates relevant and needed, but also challenging.
Areas covered: To improve this knowledge, tailoring research tools as well as
building research networks and clinical research skills for neonates are
urgently needed. Tailoring of research tools is illustrated using the develop-
ment of dried blood spot techniques and the introduction of micro-dosing
and -tracer methodology in neonatal drug studies. Both techniques can be
combined with sparse sampling techniques through population modeling.
Building research networks and clinical research skills is illustrated by the
initiatives of agencies to build and integrate knowledge on neonatal pharma-
cotherapy through dedicated working groups.
Expert opinion: Challenges relating to neonatal medicine research can largely
be overcome. Tailored tools and legal initiatives, combined with clever trial
design will result in more robust information on neonatal pharmacotherapy.
This necessitates collaborative efforts between clinical researchers, sponsors,
regulatory authorities, and last but not least patient representatives and
society.
Keywords: agency initiatives, clinical pharmacology, covariates, dried blood spot, mechanism
based models, microdosing, microtracer, neonatal networks, newborn
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1. Introduction
Drug development depends on clinical pharmacology which intends to predict drug
effects based on pharmacokinetics (PK) and pharmacodynamics (PD). These prin-
ciples also apply to children, including neonates. Neonates are the group of children
from birth up to and including the age of 27 days or the equivalent maturational age
(44 weeks postmenstrual age) and include term and preterm neonates. They repre-
sent a particularly vulnerable subgroup of the pediatric population. Fast develop-
mental changes during the neonatal period result in extensive PK/PD variability,
making pharmacotherapy (e.g., appropriate formulation, dose) and research in
this subpopulation even more specific [1-3]. Moreover, only a limited number of
subjects is available in every individual unit, since studies are performed in neonates
suffering from a particular disease. Besides this logistical issue, there are also ethical,
economical and practical obstacles. Consequence and despite the legal initiatives,
newborns remain one of the last therapeutic orphans [4,5].
1.1 From challenges to opportunities: limited drug labeling changes
despite legal initiatives
The federal US legislation and European initiatives resulted in a notable increase in
pediatric studies and in pediatric labeling changes [6]. Unfortunately, very few were
relevant to neonates. In a recent analysis on 406 pediatric labeling changes under the
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Federal Legislation, only 6% of these label changes included
neonates. These changes involved 23 drugs for 11 indications
(e.g., linezolid, rocuronium, remifentanil, sevoflurane, stavu-
dine, nevirapine) [4,5].
A recent analysis of the number of neonates planned for
enrollment in clinical development studies over a 3-year period
suggested that only 33,200 neonates were planned annually
(2011 -- 2013, Evaluate Pharma, query tool that pulls data
mainly from clinicaltrials.gov). The majority (> 31000 cases)
related to studies initiated by non-industry (academic)
sponsors, while only about 4 -- 5% were industry requested,
suggesting that there is limited research activity that will lead
to labeling changes [Pam Simpkins, pers. commun.].
In this paper, we aim to describe challenges and influences
related to neonatal medicines research. This includes newly
emerging tools to facilitate studies in neonates (e.g., dried
spot blood (DSB), micro-tracer and -sampling studies, differ-
ent PK/PD models), but also burdens related to the effective
organization of studies, covering the need to build networks
and research capacity. These topics will be preceded by an
introduction on PK and PD in neonates to illustrate the
need to for tailored dosing, and neonatal formulations.
1.2 Principles of neonatal pharmacokinetics
and -dynamics
Newborns differ from children and adults in their drug
response. These differences may be caused by changes in PK
and/or PD. The PK processes considered are absorption,
distribution, metabolism and excretion (ADME), while PD
comprises the physiological and biological response to admin-
istered drug and represent both efficacy and safety. Matura-
tional changes in neonatal period can significantly affect all
PK processes, as well as PD [1-3]. Besides maturational
changes, newly emerging covariates like treatment modalities
(e.g., hypothermia, extracorporeal circulation), environmental
issues (microbiome, critical illness, co-medication) or
pharmacogenetics further intensify the PK/PD variability in
early infancy [7].
The absorption of drugs is affected by age, formulation,
dose or route of administration as well as by food and other
drugs that interact. For example, in neonates intra-gastric
pH is elevated (> 4) which may increase bioavailability of
acid-labile compounds (penicillin G) and decrease bioavail-
ability of weak acids (phenobarbital) when given orally [1].
Additionally, gastric emptying in neonates is delayed, which
means that also duodenal absorption of drugs (e.g., paraceta-
mol) is slower in neonates [8]. Characteristics that affect
absorption and unpredictable PK of drugs administered intra-
muscularly include decreased muscle mass, decreased contrac-
tility and reduced overall muscular perfusion [1]. A specific
issue in neonates is the unanticipated higher absorption of
drugs administered transdermally due to proportionally
higher body surface area and a more permeable skin. These
differences are even more pronounced in premature neonates.
For example, topical anesthetics may result in methemoglobi-
nemia because of higher absorption and reduced capacity to
metabolize these compounds [9]. Finally, rectal absorption is
generally increased in neonate, but also variable due to the
difference in rectal venous drainage systems [8].
Differences in distribution of the drug relate to body com-
position, systemic and regional blood flow, plasma protein
binding, as well as permeability of membranes. The body
composition in early infancy changes rapidly, resulting in an
age-dependent proportion of body water and fat. Hydrophilic
drugs like aminoglycosides have a larger volume of distribu-
tion in neonates that can be explained by larger extracellular
fluid (40 -- 45% of the body weight) compared to 25 -- 30%
at the end of infancy and to 20% in adults [10,11]. On the other
side, neonates have a decreased drug protein binding capacity.
Clinical implications of alterations in drug protein binding
are most relevant for drugs which are highly protein bound
and have a narrow therapeutic index [12]. To illustrate this,
both differences in protein binding characteristics and their
covariates within neonates as well as compared to other
populations have recently been described for cefazolin [13,14].
Both absorption and distribution is in part also guided by
active transport, but data on the ontogeny of transporters
and its covariates are almost absent.
In general, drug metabolism is low in neonates and pheno-
typic, age-driven activity of drug-metabolizing enzymes is
considered as a main contributor to the PK differences
between neonates, children and adults. However, this does
Article highlights.
. Despite the legal initiatives taken in different parts of
the world to stimulate pediatric drug research, the
available knowledge on neonatal clinical pharmacology
is still lagging behind.
. The key feature of neonatal physiology is fast
maturation, resulting in extensive variability in PK and
PD, further aggravated by other covariates.
. To improve both the quantity and quality of the
knowledge on neonatal pharmacotherapy, tailored
research tools as well as building research networks and
clinical research skills are needed.
. We illustrate the feasibility to tailor research tools to
neonates by the clinical use of dried spot blood
sampling strategies, micro-dosing and -tracers in
neonatal studies. Population pharmacokinetic
approaches are based on estimations of mean and
variances through merging of information from all
observations.
. Both FDA and European Medicines Agency (EMA) aim
to address the lack of sufficient labeling information for
neonates, either through a Neonatal Subcommittee of
the Pediatric Advisory Committee or by introducing
expertise of neonatologists. EnprEMA (European
Network of Paediatric Research at the European
Medicines Agency) is also considering establishing a
working group on neonatal pharmacotherapy.
This box summarizes key points contained in the article.
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not exclude extensive inter-individual variability within the
neonatal population [15,16]. In addition, renal function and
liver flow are influenced by physiological changes depending
on age, for example, the glomerular filtration rate (GFR) in
full term neonates is 35% of the adult values [17,18]. Term neo-
nates have a rapid increase in GFR during the first 2 weeks of
life and reach adult values by the first year of life [17,18]. Prema-
ture infants show similar trends, with a slower initial rise in
GFR due to nephrogenesis not being completed until 34 weeks
of gestation [18,19]. Active tubular secretion and tubular reab-
sorption are also immature at birth (20 -- 30% of adult values),
reaching adult values by 7 -- 12 months of life [20].
Differences in neonatal physiology can also affect PD,
resulting in differences in drug efficacy or toxicity. Age-related
developmental changes in the functionality or expression of
receptors, and differences in disease status may alter the phar-
macological response to drugs [1,21,22]. For example, inotropic
agents in neonatal myocardium act in a more limited fashion
than in children or adults. This is due to a lower ratio of active
myofilaments to non-contractile elements, greater stiffness of
the ventricle, underdeveloped cardiac sympathetic nerves
and higher cardiac output per unit surface area [23]. Further-
more, immaturity can result in an altered risk of drug toxicity,
even a decreased risk. To illustrate this, neonates appear to be
less susceptible to renal toxicity induced by aminoglycosides
compared to children and adults, due to reduced intracellular
accumulation of these compounds in the renal tubular cells
[24,25]. Similar to the expansion of biomarker research in
human (adult) medicine, there is an active search for robust
biomarkers to evaluate interventions in neonates and infants.
A biomarker is a characteristic or quantitative indicator that
reflects either normal biologic or pathological processes, or
pharmacological responses or (side)-effects. This includes
imaging techniques, analysis of samples (blood, urine, saliva)
but also covers questionnaires or long-term neurodevelop-
mental outcome assessment. However, the introduction of
these biomarkers first needs robust validation in this popula-
tion. This has recently been illustrated, for example, plasma
creatinine or cystatin C as biomarkers of renal function in
early infancy [26,27]. The emerging field of metabolomics in
plasma, urine or maternal milk may provide unique insight
into the host’s dynamic behavior in different neonatal condi-
tions, including drug exposure and its effects [28]. Although
promising, the metabolomics markers have to undergo pro-
spective validation before such markers can be integrated in
clinical care or clinical research.
The issue of maturational PK and PD is not limited to the
active compounds, but should also consider excipients. The
use of potentially toxic excipients in medicines given to neo-
nates is not rare, as they are present in many commonly
used drug products [29,30]. Recent observational studies con-
firmed the almost uniform exposure to relevant excipients
(e.g., propylene glycol, ethanol, benzyl alcohol) in the UK
and Estonian cohorts of neonates [31,32]. In order to establish
safe limits for excipients, the European and US Pediatric
Formulation Initiatives have developed a Safety and Toxicity
of Excipients for Pediatrics (STEP) database, aiming to
centralize any available excipient safety and toxicity data [33].
Similarly, the European Study of Neonatal Excipient Expo-
sure project aims to assess neonatal exposure to potentially
toxic excipients [32]. PK and PD data for specific excipients
(propylene glycol, methyl- and propyl-parabens) have recently
been reported [34-36].
In summary, a large number of variables influence the dis-
position of active ingredients and excipients in neonates. The
overall effect of these variables is very difficult to predict so
that it is necessary to conduct PK studies in neonates, if
only to validate predictions form carefully constructed predic-
tive models (cf infra, 2.3). It may be necessary to use
age-specific formulations since excipients that are safe in other
age groups may be harmful in neonates, while highly concen-
trated formulation may result in additional unexplained
variability in drug exposure. To illustrate this, we refer to
our observation on the impact of the introduction of a pediat-
ric vial (50 mg/ml) instead of an adult vial (250 mg/ml) on
amikacin clearance predictability and dose accuracy [37].
2. Opportunities and influences to improve
neonatal medicines research
We aim to describe opportunities and influences related to
neonatal medicines research. This includes newly emerging
tools, tailored to conduct studies in newborns (e.g., DSB,
micro-tracer and -sampling studies, different PK/PD models),
but also burdens related to the effective organization of stud-
ies, covering the need to build networks and research capacity.
2.1 DSB sampling strategies
Collection of blood samples to estimate PK or PK/PD in
neonates is hampered by ethical issues as well as technical
challenges, since PK studies in general rely on repeated quan-
tification of drug levels in the blood compartment. The EMA
guideline recommends (not evidence based and legally not
binding, but strong commitment) for blood sampling in neo-
nates that ‘trial-related blood loss […] should not exceed 3%
of the total blood volume during a period of four weeks and
should not exceed 1% at any single time’ [38]. This means
that maximum volume of total blood (75 -- 80 ml/kg) that
can be safely removed from a 500 g preterm for trial purposes
is 1.2 ml over 4 weeks and 0.4 ml/sample. For a term
newborn (3.5 kg), this is 6 ml and 2 ml, respectively. Conse-
quently, PK studies in neonates should be designed and
performed within these blood sampling limitations that cover
both PK and safety labs, Methods to limit blood sampling
volume and frequency are encouraged to be used and devel-
oped as well as alternative methods to using blood [38]. DSB
samples, combined with population PK modeling techniques
is one potential method for facilitate PK studies in neonates
[39,40]. Interestingly, the same rationale can be built for
preclinical PK studies in small animals.
Neonatal medicines research: challenges and opportunities
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DSB refers to a blood sampling technique where small
volumes of blood are spotted on an appropriate filter paper,
dried and subsequently shipped for analysis. The technique
itself has been introduced already a long time ago in neonatal
care to screen for phenylketonuria, and became well estab-
lished for applications such as the broader neonatal screening
for inborn (metabolic) diseases. The same methodological
approach has more recently experienced a novel surge of
interest in the context of drug development, that is, toxicoki-
netic and PK studies, and of clinical pharmacotherapy, that is,
therapeutic drug monitoring (TDM) [35,41-50].
The specific area where DBS is complicated is the bio-
analysis. Although the preparation of plasma from whole
blood can also be considered a pre-analysis sample prepara-
tion, the use of DSB as material is different. Extracting
analytes of interest (e.g., mother compound, metabolites,
excipients, different drugs) that are trapped in denatured pro-
tein matrix on a filter paper requires careful optimization and
standardization. Among other issues, the optimization of the
extraction and the selection of the card type are specific
questions that should be considered [44,47]. Obviously and in
contrast to serum or plasma analysis, the underlying DBS
matrix is whole blood. Variability in hematocrit was the single
most important factor that affected assay accuracy. Neonates
exhibit considerable inter and intra-individual variation in
hematocrit values during the first 28 days of life, in part
explained by age or disease characteristics. Using dexametha-
sone as illustration, Patel et al. evaluated different factors,
including blood volume, blood hematocrit and spotting
device that may affect drug quantification measurements
based on DBS [44]. These authors hereby documented that
the assay accuracy and precision values remained within the
15% variability limit with fluctuations in hematocrit of 5%.
Variations in the volume of blood spotted did not appear to
affect the performance of the developed assay. Similar obser-
vations were made regarding the spotting device used.
Because of the low volumes, and low amounts, sensitive
and specific tools like liquid chromatography with single qua-
druple mass spectrometry (LC-MS) and more often tandem
mass spectrometry (LC-MS/MS) quantification techniques
are commonly used to develop measurement methods. The
development of such methods to measure a range of environ-
mental toxicants, excipients or drugs in DBS has been a more
recent goal. The approach has been proved to be effective in
the field of neonatal pharmacology, based on compound-
specific reports, for example, caffeine, diphantoine or
fenytoine, topiramate, canrenoate, propranolol, linezolid,
metronidazole or dexamethasone [39-44,49,51].
Interestingly, others also reported on the simultaneous
measurement of different compounds (e.g., rifampicin, clari-
thromycin and its metabolites) in the same sample [48], or
used the DBS technique to quantify prenatal ethanol exposure
(i.c. phosphatidylethanol) [45], to quantify temporal trends in
exposure to environmental chemicals (i.c. polychloridated
biphenyls and organochlorine pesticides) [46]. Finally, the
same approach has been used to quantify excipient exposure
(i.c. methyl- and propyl-parabens) in neonates [35]. In
contrast, we quantified propylene glycol exposure based on
plasma samples [34], but were unable to retrieve this com-
pound in DBS. We hypothesize that this is due to evaporation
during the drying procedure following sample collection.
Similar, benzyl penicillin and other b-lactam antibiotics may
be too unstable for DSB analysis.
2.2 Microdosing and microtracers
Quantitative assessment of metabolites in early phase of clin-
ical product development remains an analytical challenge
when commonly used methods, standards and assays like
HPLC or similar are not yet available. The use of tracers
through radioisotopic labeling, commonly with 14C, is the
preferred method to explore and quantify the absolute yields
of different metabolic routes in the absence a priori knowl-
edge of the human metabolism [51,52]. In a ‘microdose clinical
trial’, candidate compounds are administered in limited doses
estimated at not having pharmacological or toxicological
effects, aimed at candidate selection for proceeding to clinical
development starting from Phase I. Such a dose is defined as
1% of either the No Observed Adverse Effect Level
(NOAEL), or the predicted pharmacological dose based on
animal data, or 100 mg of the new compound [51,52]. Dose
linearity between the microdose and the (assumed) therapeu-
tic dose is a prerequisite to extrapolate initial findings to
dosing guidelines.
Because of the very low doses, microdosing only became
feasible due to the development of high-performance analyti-
cal technologies, such as AMS (accelerator mass spectrometry)
and LC/MS/MS (liquid chromatography/mass spectrometry/
mass spectrometry). This is because these technologies enable
determination and quantification of compound (mother com-
pound, metabolites) at very low concentration or amount in
samples collected following administration of a very limited
dose. Based on these technology and study approach, data
on the metabolism of a drug candidate can be obtained in
early development of the product by administering a
14C-drug to adults volunteers or patients, and comparing
the plasma concentration--time curves for total 14C and
unchanged parent compound. Full metabolic profiles can be
generated as an early indication of the drug’s metabolism in
humans or absolute bio-availability can be estimated [51,52].
More recently, the practice of microdosing has extended to
other areas of drug development, including in vivo drug--drug
interactions in human adults, but also explorative studies in
special populations, including newborns [53-55]. This practice
builds further on clinical experience with the use of stable
isotopes in neonates to quantify carbohydrate, fat and amino
acid metabolism or synthesis of specific peptides or
proteins [56]. In this way, the use of isotopes to describe
drug disposition is an additional application of a methodol-
ogy already in practice in pediatric clinical research and
J. Samardzic et al.
4 Expert Opin. Drug Metab. Toxicol. (2015) 11 (7)
Ex
pe
rt 
O
pi
n.
 D
ru
g 
M
et
ab
. T
ox
ic
ol
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
K
 U
 L
eu
ve
n 
on
 0
5/
11
/1
5
Fo
r p
er
so
na
l u
se
 o
nl
y.
further builds on the collected experience, including aspects of
feasibility and safety [56].
PK studies in neonates are commonly limited by the small
volume of blood that can be collected. The high sensitivity of
the above-mentioned analytic technologies (AMS, LC/MS/
MS) facilitates PK studies by reduction of the sample volumes
needed. To the very best of our knowledge, there are at
present two compounds (14C-ursodiol and paracetamol) to
illustrate at least the feasibility to apply such study methodol-
ogy (microdosing, microtracer) in neonates [53-55]. Gordi et al.
reported on the repeated administration of 14C-ursodiol
microdosing in 5 non-cholestatic and 3 cholestatic newborns,
together with 40 mg/kg of non-labeled ursodiol [54].
Besides low sampling volumes, quantifying exogenous doses
against the endogenous background was feasible by the 14C
tracer molecule. Two consortia evaluated 14C-paracetamol
metabolism using AMS technology in infants. Mooij et al.
reported on 10 newborns, infants and toddlers (0.3 -- 83.1
months) who were simultaneously exposed to an oral 14C
microdose (3.3 ng/kg) in addition to a regular intravenous
paracetamol dose (15 mg/kg, q6h) (microtracer approach).
The authors hereby documented paracetamol disposition in
their cohort. Using a similar approach, a multi-centre clinical
study to evaluate the use of a microtrace dose of 14C-labelled
Paracetamol and AMS bio-analysis (PAMS study) as new tools
in drug development to determine PK in 60 preterm and term
neonates, infants and toddlers was recently finalized [53,55].
These studies also used ‘microdoses’ where the 14C label was
administered separately from a therapeutic dose. Interestingly,
DBS analysis was not possible in these studies because the
background rates of 14C in filter paper were too high and
non-cellulose based papers were not useful.
At least, the available data provide a proof of concept and
feasibility that microdosing and microtracer study approaches
are indeed possible in neonates. It hereby still needs to be
proven that the dose linearity between the microdose and
the therapeutic dose also exist in early infancy.
2.3 Population modeling in early infancy
About 30 years after its introduction, PK population
approaches became the reference approach for drug modeling
in pediatrics and early infancy. In silico prediction of PK
behavior in pediatric patients is not intended to replace
clinical studies. However, it provides a valuable aid to
decision-making with regard to first-time dosing in children
and study design. The clinical study then becomes
’confirmatory’ rather than ’exploratory’ [57-62]. Regulatory
bodies increasingly encourage the use of modeling and
simulation methods for all pediatric drug development pro-
grams [63] which also is reflected in a number of regulatory
guidance documents [64]. This is because the main limitations
in this specific population is the blood volume to be collected
and -- related to this -- sampling frequency, and the number of
patients to be recruited. PK population approaches using
sparse sampling may resolve both issues. Population PK
approaches are based on estimations of mean and variances
through merging of information from all observations
(concentration/time, concentration/effect) in all individual
patients. Therefore, every effort should be made to simulta-
neously collect data on covariates to unveil indicators related
to maturational changes in PK or PD. Consequently, it is
advisable to include data on covariates like gestational age,
postnatal age, postmenstrual age, birth weight, body weight,
renal function, albumin, concomitant medication or
co-morbidity in PK/PD studies [57-62]. Guidance is generated
through, for example, the EMA modeling and simulation
work group and workshops are organized on this topic [65,66].
Drug modeling can be considered to be a success when
such an exercise can support a decision, for example, initial
dose to be studied in a study, tailored individualized dosing
in the clinical setting, or anticipate the extent of drug-drug
interactions. Depending on the underlying distribution of
parameters or covariates, both parametric and non-parametric
estimation methods can be used. Datasets limited to or
including preterm and term newborns hereby present the
biggest challenge, since such datasets display an extensive
range in addition to mean or median estimates. The rapid
developmental changes in ADME, combined with all possible
disease processes that interfere with these developmental
changes (‘ontogeny’), necessitate a study design that is suffi-
ciently powered to estimate mean values but also to quantify
the impact of covariates.
There are in essence two different approaches, either
physiologically based pharmacokinetics (PBPK) or empiric,
exploratory model building. PBPK models aim to translate
anatomical, physiological, physical and/or chemical descrip-
tions of all phenomena involved in the complex drug disposi-
tion process to predict concentration/time or concentration/
effect patterns. PBPK modeling offers a unique method to
incorporate different levels of information (drug physico-
chemical properties, preclinical data, clinical data) to estimate
age-specific PK [60,62]. Although a degree of simplification and
empiricism is still present in such PBPK models, they have an
extended domain of applicability compared to that of classi-
cal, empirical based models. The main advantage of PBPK
models is that prediction becomes possible, while empirical-
based models need preliminary observations, although also
PBPK models are most informative when supported or
improved by empirical data [10,59,62]. Any population PK
approach can account for covariates within a given pediatric
population, but they generally do not account for real-time
growth and maturation of individuals through the time course
of drug exposure [63]. Integration of time-varying system
parameters (‘re’sampling) during prolonged studies to correct
for subject maturation has been reported to provide more
robust predictions. Obviously, re-sampling was most frequent
in early neonatal life, reflecting the fast maturational changes
in this subgroup [63].
Unfortunately, the available knowledge on developmental
physiology in early infancy is still too limited, particularly in
Neonatal medicines research: challenges and opportunities
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preterm neonates. This is at present also reflected in the fact
that the most commonly used PBPK modeling tools (i.c.
Symcyp, PK-Sim) do not yet contain robust information on
preterm neonates [54,67]. This includes, but is not limited to
the physiological parameters driving oral absorption through-
out early infancy. To illustrate this, we would like to refer to a
very recently published paper on PBPK-based modeling using
both software packages mentioned to predict oral drug expo-
sure over the entire pediatric age range. Using sotalol as a
model drug, both PBPK software packages evaluated reflected
properly the age-related PK changes and predicted adequately
the oral sotalol exposure in children of different ages, except
in neonates where an above twofold error was observed [67].
These differences were likely explained by controversies and
knowledge gaps on neonatal development of the gastrointesti-
nal tract and functions [68].
The same limitations also hold true for other reported
examples, including a PBPK model for voriconazole (no esti-
mates below 2 years) [69], theophylline and midazolam (term
neonates) [70], caffeine and theophylline (term neonates) [71].
Based on prediction of clearance of 11 drugs (including
midazolam, caffeine, cisapride, omeprazole, gentamicin, van-
comycin) and its associated variability in neonates, infants
and children, the accuracy of the physiologically based model
incorporated in the Simcyp software was superior to that of
simple allometry, especially in children < 2 years old [72]. Still,
only 70% of the predicted median clearance values were
within the twofold of the observed values, compared to
89 -- 100% in the other pediatric age categories. To the best
of our knowledge, PBPK examples in preterm neonates have
only been reported as abstracts (aminoglycosides, paraceta-
mol) [73,74].
Translation of the already available knowledge, either
implicitly hidden in mechanism-based models or explicitly
integrated in physiologically based population PK/PD models
hold the promise to facilitate drug evaluation in (pre)term
neonates, to explore the impact of covariates and to design
studies in the most effective manner [59,63]. This combined
use of both modeling approaches (‘semi-physiological models)
is of relevance, since we do not have (yet) sufficient data on the
developmental physiology in early life. The maturational
patterns described and the extent of the impact of covariates
can subsequently be applied to predict in vivo concentration-
time profiles for compounds that undergo similar routes of
elimination. This concept has been applied for developmental
glucuronidation and developmental GFR [10,75].
In this way, such in vivo observations can also be used as a
“bottom-up” approach to learn more about the maturational
patterns, and to guide research on gaps in the knowledge on
developmental anatomy and physiology. PK/PD models do
not only hold promise ‘top-down’ to design studies, but
may also serve as indicators to guide research on developmen-
tal physiology as ‘confirmatory’ instead of ‘exploratory’.
Improved knowledge on developmental pharmacology hereby
does not only support the individualized drug prescription,
but can also improve the knowledge on aspects of develop-
mental biology that are not yet fully understood, or difficult
to explore in the human newborn (e.g., drug-drug interaction,
transporter activity).
2.4 Legislation driven initiatives
The federal US legislation and consecutively, the European
Paediatric Regulation resulted in a notable increase in pediat-
ric studies and in a relevant increase in labeling changes.
Unfortunately, only few of these changes included drug label-
ing changes for neonates [4,5] and an EMA survey confirmed
that (pre)term newborns are the age group with the highest
‘off-label’ use reported in Europe [76]. This induced in both
agencies initiatives to stimulate neonatal medicines research.
FDA and EMA encourage a coordinated collaborative
approach to product development, including formulations,
as an important step towards more effective product develop-
ment for neonates.
The FDA is working to address the lack of sufficient label-
ing information for neonates. This is achieved through estab-
lishing a Neonatal Subcommittee of the Pediatric Advisory
Committee and by introducing expertise of neonatologists
to assist FDA in establishing priorities and scientific pathways
for neonatal product development [77]. This initiative is part
of the recently revised Food and Drug Administration Safety
and Innovation Act (FDASIA, 2012) and may be an impor-
tant driver to stimulate neonatal pharmacological research.
According to EU legislation companies have to obtain the
approval, from the European Medicines Agency (EMA), of
the studies to be done with neonates or children well in
advance of their application for marketing authorization in
adults. The Paediatric Investigation Plan to be agreed with
the Paediatric Committee at the EMA (PDCO/EMA) needs
to discuss the development program, specifically including
neonates, describing the development of neonatal age-
appropriate formulation as well as the specific non-clinical
and clinical development required (if any) for all pediatric
age subsets. PDCO from its beginning placed great emphasis
to ensure that the neonatal population is adequately covered.
This significantly increased the percentage of PIPs including
neonatal studies, compared to the initial proposal of pharma-
ceutical companies: from 15 to 28% in January--October
2008 [78], and from 24 to 32% in March--December 2011
[76]. This is not reflected in any changes of authorization as
the completion of most neonatal studies has been deferred,
that is, can take place after the adult development. In order
foster and focus on the drug development for this age group,
the PDCO created in 2013 a Neonatal Working Group com-
prised of pediatricians including neonatologists and pediatric
intensive care specialists as well as formulation and methodo-
logical specialists. The main area is to provide support for the
review of product specific PIPs with regard to neonatal issues.
This group collaborates closely with Enpr-EMA (European
Network of Paediatric Research at the European Medicines
Agency), which also has established a working group with
J. Samardzic et al.
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specific emphasis on neonatal pharmacotherapy. Enpr-EMA
develops a network of networks, investigators and centers
with specific expertise in the performance of studies in the
pediatric population. The mission hereby is to facilitate drug
trials in order to improve the availability of labeled, autho-
rized medical products. This is obviously not limited to, but
includes neonatology. The aims of this working group are to
provide further expertise to the Paediatric Committee
(PDCO), for example, with respect to the review and update
of the EMA guideline on the investigation of medicinal prod-
ucts in term and preterm neonates [38], the inventory on
therapeutic needs in neonates and the impact of 10 years of
the Paediatric Regulation on data generated in (pre)term
neonates. Last but not least, the working group aims to collab-
orate with learned societies on, for example, trial design, the
validity of extrapolation, the use of biomarkers, or the assess-
ment of long-term outcomes. The inclusion of the youngest
pediatric age-groups also has led to an increase of numbers
of juvenile animal studies [79]. Further research is needed
regarding the impact of the use of preclinical models and tox-
icity studies specifically for the neonatal drug development.
Regulatory tools and methods (e.g., qualification of method-
ologies, scientific advice and protocol assistance, innovative
task force activities) should be considered as support from
the regulators. In the end, these methods will have to be
used when evaluating and assessing novel medicines for
neonates [80].
2.5 Caregivers and trials in neonates
Obviously, the general regulatory guidelines on best practice
in research should also be applied when conducting a study
in newborns [76,77]. However, there are some issues that are
worth considering because of the specific contextual factors
relevant to studies in neonates. Before starting a study, care-
givers of a given neonatal unit should be aware that the needs
to conduct a given study in line with the guidelines may
disrupt or intervene with local practices or routine proce-
dures [81]. Thorough process mapping is crucial, taking both
into account the specific aspects of the unit (e.g., protocols,
referral, safety procedures) and the requirements of a given
study trial (type of patients, duration of the study, data to
be collected). No study can be implemented by the study
team alone and a study will impact on all caregivers in the
unit. Trials that recruit shortly after birth, benefit from prena-
tal information on the ongoing trials, while formal consent is
best obtained after delivery [81].
As described above, most of the currently conducted studies
were initiated by non-industry, academic sponsors. Clinicians
commonly use a pragmatic, randomized trial design, while
more sophisticated, advanced trial designs as well as a broader
‘product development approach’ should be considered to
make most use of the high quality data. Issues not commonly
considered include, for example, product stability, compati-
bility, dose selection, or the concept of adverse events versus
adverse effects.
For example, several large-scale trials of inhaled nitric oxide
for extremely preterm infants have been conducted in the
absence of evidence relating to the optimal dosage regimen or
inclusion criteria [82]. Initiatives in Europe and the US have
funded research into off-patent medicines that have demon-
strated that a structured drug development program is possible
in neonates [81]. Neonatologists should insist on incorporation
of evidence-based treatment sufficient to support product
labeling in neonates [7,81,83-85]. Journal publication and expert
opinion are in general not sufficient for labeling.
Issues or problems related to clinical investigators as men-
tioned by the FDA during the webinar are the insufficient
documentation of parental permission, insufficient documen-
tation of the institutional review board (IRB), problems
related to the reproducibility of laboratory tests, inability to
validate documentation, poor quality of data or inability to
enroll or follow patients [86]. Further issues relate to having
and document sufficiently safety data, including appropriate
long-term (efficacy and safety) data specifically for neonates.
Be aware: for a monitor or a regulatory body: ‘what has not
been documented and stored and consequently, cannot be
verified, never happened’. Clinicians may be content with
data that are sufficient for publication because they have the
ability to monitor their patients after a medicine is adminis-
tered. If imperfect data led to inaccurate results then clinicians
can adapt to the consequences in real time. Regulators cannot
monitor individual patients and so have to be assured of the
quality of the data before grant a marketing authorization or
license. This does not mean that ‘off label is equal to off
knowledge’ in an individual newborn, but the final aim
should be marketing authorization and labeling.
Both issues, that is, center-specific skills and problems
related to recruitment can be addressed by building
and -- even more relevant -- maintaining research networks.
This is because the cost of building and taking down individ-
ual networks for each product development plan is prohibi-
tive [86]. While agencies can try to act as catalysts to
stimulate such network building, it is up to the individual
caregivers and neonatal units to integrate the need to contrib-
ute to neonatal medicines research and product development
as part of their mission statement [81,84-86]. At least, the output
and the impact of pediatric pharmacotherapy of either topical
networks [European Cystic Fibrosis Society, Clinical Trials
Network for cystic fibrosis (ECFS-CTN) [87], Pediatric Rheu-
matology International Trials Organization (PRINTO) [88]]
or national networks (e.g., Medicines for Children Research
Network) illustrates the potentials of network building [89].
The StaR initiative is such an attempt to try to translate the
experience built through the Medicines of Children Research
Network to address the paucity and shortcomings of pediatric
trials, including in neonates to a global level. This initiative
involves methodologists, clinicians, patient advocacy groups
and policy makers dedicated to developing practical,
evidence-based standards for enhancing the reliability and rel-
evance of pediatric clinical research [90]. The Global Research
Neonatal medicines research: challenges and opportunities
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in Pediatrics (GRIP) Network of Excellence is developing
methods and case studies to support an infrastructure for
the development of medicines in children [6].
At present, a search in the Enpr-EMA database on preterm
and/or term newborn results in 30 hits, so there is for sure
potential to build such networks. Similarly, at the latest
European Academy of Pediatric Societies (EAPS) meeting in
Barcelona (October 2014), about 60 neonatologists attended
a dedicated workshop on neonatal medicines research. About
half of the attendees had experience with FP7 projects, reflect-
ing the fact that translation from temporary, project-related
research facilities to permanent research facilities should be
feasible [83].
3. Conclusion
Despite the legal initiatives taken, the knowledge on neonatal
clinical pharmacology remains suboptimal. The key feature of
neonatal physiology is its fast maturation. As a consequence,
there is extensive variability in PK and PD in newborns.
This makes clinical research in neonates relevant, but also
more difficult. To improve the knowledge on neonatal phar-
macotherapy, tailoring of research tools as well as building
research networks and clinical research skills are needed.
We illustrate the feasibility to tailor research tools to neo-
nates by DSB sampling strategies and by the first reports on
micro-dosing and -tracers in neonates. Population pharmaco-
kinetic approaches are based on estimations of mean and
variances through merging of information. Datasets in (pre)
term newborns hereby present the biggest challenge, since
such datasets display an extensive range. Legal initiatives of
both FDA and EMA aim to address the lack of sufficient
labeling information for neonates through establishing dedi-
cated working groups.
4. Expert opinion
Newborns remain one of the last therapeutic orphans. This is
because the legal initiatives taken in different parts of the
world resulted in an increase in pediatric drug labeling
changes, but only few of these related to neonates [4,5]. Among
different challenges, only a limited number of subjects is avail-
able in every individual unit, since studies are performed in
neonates suffering from a particular disease. Besides this logis-
tical issue, there are also ethical, economical and practical
obstacles [85]. In Figure 1, we suggest a framework on how
neonatal medicines research should evolve.
Driven by an identified therapeutic need, a first step should
be to collect already existing data and maximize their use. We
refer the interested reader to the EMA concept paper on
extrapolation of efficacy and safety in medicine develop-
ment [91]. The approach taken on excipients mentioned in
the introduction (STEP, ESNEE) are illustrations of such a
structured approach [32,33]. Besides extrapolation and other
modeling approaches, there is also value in meta-analysis.
The use of ‘individual patient data’ instead of ‘aggregate data’
hereby allows exploration of effect modifications at the level
of patient characteristics. It also allows multivariate analysis
of the collected covariates, correcting for possible confound-
ing factors. Similar to the network approach as a tool to
improve neonatal medicines research, collaboration between
different research groups is hereby crucial. Such an approach
has been reported, for example, ventilation modes [92], or for
inhaled nitric oxide in preterm neonates [82,93].
In the subsequent study design, the available information,
including (partial) extrapolation from, for example, children
for efficacy of antibiotics, can be used to minimize the burden
for the individual patient. There are numerous examples on
the use of TDM data to develop and subsequently validate
PK models [10] or to illustrate its limitations related to, for
example, creatinine assays or vancomycin assays used [94].
Opportunistic sampling, that is, sample collection at times
where there is a clinical indication to collect blood, or scav-
enged samples (i.e., based on remnants initially collected for
clinical use) can be used. However, both approaches do
need a detailed registration of sampling times, dosing and
covariates. A PK model is sufficiently sophisticated to explore
the explained variability, but the extent of the unexplained
variability largely depends on the quality of data collection
(‘rubbish in = rubbish out’). Finally, one should realize that
PK modeling can also be used to develop the most informa-
tive sampling schemes, but that such schemes may result in
conflicts between clinical needs and study related needs [58,81].
Finally, one should try to minimize the number of patients
to be recruited while still being able to provide the answers
needed. A smaller study is not only cheaper, but also sooner
finalized, and data to base clinical decisions on will become
available sooner. Adaptive designs or effective dose (ED5O
or ED90) studies have been reported, for example, patent duc-
tus arteriosus and ibuprofen (continual reassessment method)
[95] or endotracheal intubation and propofol (ED50 for
endotracheal intubation) [96].
Besides tailoring research tools, another framework
(Figure 2) focuses on building networks of stakeholders active
• Maximise use of existing data
– Extrapolation
– Modeling
– Systematic review or meta-analysis
• Minimise burden for the individual patient
– Opportunistic samples
– Scavenged samples
• Minimise number of recruits
– Adaptive designs
Framework on study design
Figure 1. Framework on study design for neonatal medi-
cines research.
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in the field of neonatal medicines research. Such networks
should be interdisciplinary. This is because interaction
throughout product development is crucial. The society, and
in our population, especially young parents, should be aware
of the concepts and relevance of clinical research and the con-
sent procedure. In essence, they should be the advocates of the
adagio that ‘neonates should be protected through, not from
research’. The fact that parents or patient groups are repre-
sented in, for example, IRB’s or at the PDCO is an asset,
that should be further explored. Caregivers should be involved
in trial design, including feasibility, but also when priorities
on therapeutic needs are considered (e.g., priority list pediat-
ric off patent medicines). There may be a benefit for building
networks between sponsors (multi-drug and multi-company
studies) and support the clinical research networks. This is
because costs to build and close down individual networks
for each product development program are prohibitive.
Acknowledgments
We thank the European Society for Pediatric Research
(ESPR) for the opportunity provided to discuss neonatal
medicines research in Europe at the latest EAPS meeting
(October 2014) in a workshop. We are grateful to Pam Simp-
kins, Janssen, for supplying the data about projected recruit-
ment from clinicaltrials.gov cited in the text.
Declaration of interest
J Samardzic is supported by ERAWEB II scholarship for post-
doctoral program at the KU Leuven, Belgium (2014 -- 2015).
MA Turner is supported by the Medical Research Council
grant G1100158, European Commission Network of Excel-
lence Grant Agreement 261060, (Global Research in Paediat-
rics), and FP7 grants TINN (223614), TINN2 (260908),
NeoCirc (282533) and NeoVanc (602401). K Allegaert is
supported by the Fund for Scientific Research, Flanders (fun-
damental clinical investigatorship 1800214N) and the
research activities are further facilitated by the agency for inno-
vation by Science and Technology in Flanders (IWT) through
the SAFEPEDRUG project (IWT/SBO 130033). The views
expressed in this article are the personal views of the authors
and may not be understood or quoted as being made on behalf
of or reflecting the position of the European Medicines
Agency or one of its committees or working parties. The
authors have no other relevant affiliations or financial involve-
ment with any organization or entity with a financial interest
in or financial conflict with the subject matter or materials dis-
cussed in the manuscript apart from those disclosed.
Bibliography
Papers of special note have been highlighted as
either of interest () or of considerable interest
() to readers.
1. Kearns GL, Abdel-Rahman SM,
Alander SW, et al. Developmental
pharmacology----drug disposition,
action, and therapy in infants and
children. N Engl J Med
2003;349:1157--67
.. Extensive review on the concept of
clinical pharmacology in infants as
‘moving target’.
2. Allegaert K, Verbesselt R, Naulaers G,
et al. Developmental pharmacology:
neonates are not just small adults….
Acta Clin Belg 2008;63:16--24
3. Turner MA. Neonatal drug development.
Early Hum Dev 2011;87:763--8
4. Stiers JL, Ward RM. Newborns, one of
the last therapeutic orphans to be
adopted. JAMA Pediatr 2014;168:106--8
. Recent evaluation on the current status
of drug labeling and exposure
in neonates.
5. Laughon MM, Avant D, Tripathi N,
et al. Drug labeling and exposure in
neonates. JAMA Pediatr 2014;168:130--6
6. Turner MA, Catapano M, Hirschfeld S,
et al. Paediatric drug development: the
impact of evolving regulations. Adv Drug
Deliv Rev 2014;73:2--13
7. Allegaert K. Tailored tools to improve
pharmacotherapy in infants. Expert Opin
Drug Metab Toxicol 2014;10:1069--78
8. Anderson BJ, van Lingen RA,
Hansen TG, et al. Acetaminophen
developmental pharmacokinetics in
premature neonates and infants: a pooled
population analysis. Anesthesiology
2002;96:1336--45
9. Choonara I. Percutaneous drug
absorption and administration.
Arch Dis Child 1994;71:F73--4
10. de Cock RF, Allegaert K, Sherwin CM,
et al. A neonatal amikacin covariate
model can be used to predict ontogeny
of other drugs eliminated through
glomerular filtration in neonates.
Pharm Res 2014;31:754--67
11. Allegaert K, Langhendries JP,
van den Anker JN. Educational paper:
do we need neonatal clinical
pharmacologists? Eur J Pediatr
2013;172:429--35
12. Roberts JA, Pea F, Lipman J. The
clinical relevance of plasma protein
binding changes. Clin Pharmacokinet
2013;52:1--8
Multiple partners
Newborns and
their families Health insurance
agencies
Sponsors
Regulators
Researchers
Figure 2. Collaborative model with multiple partners
needed to facilitate neonatal medicines research.
Neonatal medicines research: challenges and opportunities
Expert Opin. Drug Metab. Toxicol. (2015) 11(7) 9
Ex
pe
rt 
O
pi
n.
 D
ru
g 
M
et
ab
. T
ox
ic
ol
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
K
 U
 L
eu
ve
n 
on
 0
5/
11
/1
5
Fo
r p
er
so
na
l u
se
 o
nl
y.
13. Smits A, Kulo A, Verbesselt R, et al.
Cefazolin plasma protein binding and its
covariates in neonates. Eur J Clin
Microbiol Infect Dis 2012;31:3359--65
14. Smits A, Roberts JA, Vella-Brincat JW,
et al. Cefazolin plasma protein binding
in different human populations: more
than cefazolin-albumin interaction. Int J
Antimicrob Agents 2014;43:199--200
15. Hines RN. Developmental expression of
drug metabolizing enzymes: impact on
disposition in neonates and young
children. Int J Pharm 2013;452:3--7
16. de Wildt SN. Profound changes in drug
metabolism enzymes and possible effects
on drug therapy in neonates and
children. Expert Opin Drug
Metab Toxicol 2011;7:935--48
. Summary on the iso-enzyme-specific
impact of ontogeny on
drug metabolism.
17. Rhodin MM, Anderson BJ, Peters AM,
et al. Human renal function maturation:
a quantitative description using weight
and postmenstrual age. Pediatr Nephrol
2009;24:67--76
18. De Cock RF, Allegaert K,
Schreuder MF, et al. Maturation of the
glomerular filtration rate in neonates, as
reflected by amikacin clearance.
Clin Pharmacokinet 2012;51:105--17
19. Smits A, Kulo A, de Hoon JN, et al.
Pharmacokinetics of drugs in neonates:
pattern recognition beyond compound
specific observations. Curr Pharm Des
2012;18:3119--46
20. Schreuder MF, Bueters RR, Allegaert K.
The interplay between drugs and the
kidney in premature neonates.
Pediatr Nephrol 2014;29:2083--91
21. Mulla H. Understanding developmental
pharmacodynamics: importance for drug
development and clinical practice.
Paediatr Drugs 2010;12:223--33
22. Stephenson T. How children’s responses
to drugs differ from adults. Br J
Clin Pharmacol 2005;59:670--3
23. Bajcetic M, Uzelac TV, Jovanovic I.
Heart failure pharmacotherapy:
differences between adult and paediatric
patients. Curr Med Chem
2014;21:3108--20
24. McWilliam SJ, Antoine DJ, Sabbisetti V,
et al. Mechanism-based urinary
biomarkers to identify the potential for
aminoglycoside-Induced nephrotoxicity
in premature neonates:
a proof-of-concept study. PLoS ONE
2012;7:e43809
25. Kent A, Turner MA, Sharland M, et al.
Aminoglycoside toxicity in neonates:
something to worry about? Expert Rev
Anti Infect Ther 2014;12:319--31
26. Allegaert K, Pauwels S, Smits A, et al.
Enzymatic isotope dilution mass
spectrometry (IDMS) traceable serum
creatinine is preferable over Jaffe in
neonates and young infants. Clin Chem
Lab Med 2014;52:e107--9
27. Allegaert K, Mekahli D,
van den Anker J. Cystatin C in
newborns: a promising renal biomarker
in search for standardization and
validation. J Matern Fetal Neonatal Med
2014;5:1--6
28. Iacovidou N, Syggelou A, Chalkias A,
et al. Metabolomics applied in
neonatology. Bioanalysis 2014;6:403--10
29. Whittaker A, Currie AE, Turner MA,
et al. Toxic additives in medication for
preterm infants. Arch Dis Child Fetal
Neonatal Ed 2009;94:F236--40
30. Standing JF, Tuleu C. Paediatric
formulations--Getting to the heart of the
problem. Int J Pharm 2005;300:56--66
31. Lass J, Naelapa¨a¨ K, Shah U, et al.
Hospitalised neonates in Estonia
commonly receive potentially harmful
excipients. BMC Pediatr 2012;12:136
32. Turner MA, Duncan J, Shah U, et al.
European Study of Neonatal Exposure to
Excipients: an update. Int J Pharm
2013;457:357--8
33. . Salunke S, Brandys B, Giacoia G, et al.
The STEP. Safety and Toxicity of
Excipients for Paediatrics) database: part
2 -- the pilot version. Int J Pharm
2013;457:310--22
34. De Cock RF, Knibbe CA, Kulo A, et al.
Developmental pharmacokinetics of
propylene glycol in preterm and term
neonates. Br J Clin Pharmacol
2013;75:162--71
35. Mulla H, Yakkundi S, McElnay J, et al.
An observational study of blood
concentrations and kinetics of methyl-
and propyl-parabens in neonates.
Pharm Res 2015;32(3):1084--93
36. Allegaert K, Vanhaesebrouck S, Kulo A,
et al. Prospective assessment of short-
term propylene glycol tolerance in
neonates. Arch Dis Child
2010;95:1054--8
37. Allegaert K, Anderson BJ, Vrancken M,
et al. Impact of a paediatric vial on the
magnitude of systematic medication
errors in neonates. Paed Perinatal
Drug Ther 2006;7:59--63
38. EMA. Guideline on the investigation of
medicinal products in the term and
preterm neonate.
2009. Available from: http://www.ema.
europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/09/
WC500003750.pdf [last accessed
28 January 2015]
39. Patel P, Mulla H, Kairamkonda V, et al.
Dried blood spot assay and sparse
sampling: a practical approach to
estimating pharmacokinetic parameters of
caffeine in preterm infants. Br J
Clin Pharmacol 2013;75:805--13
40. Suyagh M, Collier PS, Millerschip JS,
et al. Metronidazole population
pharmacokinetics in preterm neonates
using dried blood-spot sampling.
Pediatrics 2011;127:e367--74
41. Villanelli F, Giocaliere E, Malvagia S,
et al. Dried blood spots for the
quantification of phenytoin using Liquid
Chromatography-Mass Spectrometry.
Clin Chim Acta 2014;440C:31--5
42. Suyagh M, Hawwa AF, Collier PS, et al.
Potassium canrenoate treatment in
paediatric patients: a population
pharmacokinetic study using novel dried
blood spot sampling. J Hypertens
2013;31:1901--8
43. Della Bona ML, Malvagia S, Villanelli F,
et al. A rapid liquid chromatography
tandem mass spectrometry-based method
for measuring propranolol on dried
blood spots. J Pharm Biomed Anal
2013;78-79:34--8
44. Patel P, Tanna S, Mulla H, et al.
Dexmethasone quantification in dried
blood spot samples using LC-MS: the
potential for application to neonatal
pharmacokinetic studies. J Chromatogr B
Analyt Technol Biomed Life Sci
2010;878:3277--82
45. Bakhireva LN, Leeman L, Savich RD,
et al. The validity of phosphatidylethanol
in dried blood spots of newborns for the
identification of prenatal alcohol
exposure. Alcohol Clin Exp Res
2014;38:1078--85
46. Ma WL, Gao C, Bell EM, et al. Analysis
of polychlorinated biphenyls and
organochlorine pesticides in archived
dried blood spots and its application to
J. Samardzic et al.
10 Expert Opin. Drug Metab. Toxicol. (2015) 11 (7)
Ex
pe
rt 
O
pi
n.
 D
ru
g 
M
et
ab
. T
ox
ic
ol
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
K
 U
 L
eu
ve
n 
on
 0
5/
11
/1
5
Fo
r p
er
so
na
l u
se
 o
nl
y.
track temporal trends of environmental
chemicals in newborns. Environ Res
2014;133:204--10
47. Yakkundi S, McElnay J, Millership J,
et al. Use of dried blood spots to study
excipient kinetics in neonates. Bioanalysis
2011;3:2691--3
48. Vu DH, Koster RA, Bolhuis MS, et al.
Simultaneous determination of
rifampicin, clarithromycin and their
metabolites in dried blood spots using
LC-MS/MS. Talanta 2014;121:9--17
49. Vu DH, Bolhuis MS, Koster RA, et al.
Dried blood spot analysis for therapeutic
drug monitoring of linezolid in patients
with multidrug-resistant tuberculosis.
Antimicrob Agents Chemother
2012;56:5758--63
50. La Marca G, Malvagia S, Filippi L, et al.
Rapid assay of topiramate in dried blood
spots by a new liquid chromatography-
tandem mass spectrometric method.
J Pharm Biomed Anal 2008;48:1392--6
51. Beaumont C, Young GC, Cavalier T,
et al. Human absorption, distribution,
metabolism and excretion properties of
drug molecules: a plethora of approaches.
Br J Clin Pharmacol 2014;78:1185--200
.. Recent overview on the available
approaches to assess absorption,
distribution, metabolism and excretion
of drugs in humans.
52. Vuong LT, Blood AB, Vogel JS, et al.
Applications of accelerator MS in
pediatric drug evaluation. Bioanalysis
2012;4:1871--82
53. Garner RC, Park BK, French NS, et al.
Observational infant exploratory [14C]
paracetamol pharmacokinetic microdose/
therapeutic dose study with accelerator
mass spectrometry bioanalysis. Br J
Clin Pharmacol
2015. [Epub ahead of print]
54. Gordi T, Baillie R, Vuong Le T, et al.
Pharmacokinetic analysis of 14C-ursodiol
in newborn infants using accelerator mass
spectrometry. J Clin Pharmacol
2014;54:1031--7
55. Mooij MG, van Duijn E, Knibbe CA,
et al. Pediatric microdose study of [14C]
paracetamol to study drug metabolism
using accelerated mass spectrometry:
proof of concept. Clin Pharmacokinet
2014;53:1045--51
56. Schierbeek H, van den Akker CH,
Fay LB, et al. High-precision mass
spectrometric analysis using stable
isotopes in studies of children.
Mass Spectrom Rev 2012;31:312--30
57. Himebauch AS, Zuppa A. Methods for
pharmacokinetic analysis in young
children. Expert Opin Drug
Metab Toxicol 2014;10:497--509
. Review on the tailored methods to
study pharmacokinetics in
young children.
58. Laughon MM, Benjamin DK Jr,
Capparelli EV, et al. Innovative clinical
trial design for pediatric therapeutics.
Expert Rev Clin Pharmacol
2011;4:643--52
.. Key paper on innovative trial design to
facilitate the pediatric drug
development process.
59. De Cock RF, Piana C, Krekels EH,
et al. The role of population PK-PD
modelling in paediatric clinical research.
Eur J Clin Pharmacol
2011;67(Suppl 1):5--16
60. Barrett JS, Della Casa Alberighi O,
La¨er S, et al. Physiologically based
pharmacokinetic (PBPK) modeling in
children. Clin Pharmacol Ther
2012;92:40--9
61. Anderson BJ, Allegaert K, Holford NH.
Population clinical pharmacology of
children: general principles. Eur J Pediatr
2006;165:741--6
62. Maharaj AR, Edginton AN.
Physiologically based pharmacokinetic
modeling and simulation in pediatric
drug development.
CPT Pharmacometrics Syst Pharmacol
2014;3:e150
63. Abduljalil K, Jamei M,
Rostami-Hodjegan A, et al. Changes in
individual drug-independent system
parameters during virtual paediatric
pharmacokinetic trials: introducing time-
varying physiology into a paediatric
PBPK model. AAPS J 2014;16:568--76
. Integration of the age-dependent
‘moving target’ concept in
PBPK studies.
64. Manolis E, Osman TE, Herold R, et al.
Role of modeling and simulation in
pediatric investigation plans.
Paediatr Anaesth 2011;21:214--21
65. Zisowsky J, Krause A, Dingemanse J.
Drug development for pediatric
populations: regulatory aspects.
Pharmaceutics 2010;2:364--88
66. European Medicines Agency. European
Medicines Agency modelling and
simulation working group plan.
2014. Available from: http://www.ema.
europa.eu/docs/en_GB/document_library/
Other/2014/06/WC500167816.pdf [last
accessed 15 February 2015]
67. Khalil F, La¨er S. Physiologically based
pharmacokinetic models in the prediction
of oral drug exposure over the entire
pediatric age range-sotalol as a model
drug. AAPS J 2014;16:226--39
68. Yu G, Zheng QS, Li GF. Similarities
and differences in gastrointestinal
physiology between neonates and adults:
a physiologically based pharmacokinetic
modeling perspective. AAPS J
2014;16:1162--6
69. Zane RN, Thakker DR.
A physiologically based pharmacokinetic
model for voriconazole disposition
predicts intestinal first-pass metabolism
in children. Clin Pharmacokinetic
2014;53:1171--82
70. Bj€orkman S. Prediction of drug
disposition in infants and children by
means of physiologically based
pharmacokinetic (PBPK) modelling:
theophylline and midazolam as model
drugs. Br J Clin Pharmacol
2005;59:691--704
71. Ginsberg G, Hattis D, Russ A, et al.
Physiologically based pharmacokinetics-
(PBPK) modeling of caffeine and
theophylline in neonates and adults:
implications for assessing children’s risks
from environmental agents.
J Toxicol Environ Health A
2004;67:297--329
72. Johnson TN, Rostami-Hodjegan A,
Tucker GT. Prediction of the clearance
of eleven drugs and associated variability
in neonates, infants and children.
Clin Pharmacokinet 2006;45:931--56
73. Claassen K, Willmann S, Thelen K,
et al. Physiology-based simulations of
amikacin pharmacokinetics in preterm
neonates. Annual meeting of the
Population Approach Group in Europe
(PAGE). Berlin, 2010; abstract 1859
74. Claassen K, Willmann S, Thelen K,
et al. Evaluation of a PBPK model for
preterm neonates by predicting
paracetamol pharmacokinetics. Annual
meeting of the Population Approach
Group in Europe (PAGE). Athens, 2011;
abstract 1978
75. Krekels EH, Neely M, Panoilia E, et al.
From pediatric covariate model to
semiphysiological function for
Neonatal medicines research: challenges and opportunities
Expert Opin. Drug Metab. Toxicol. (2015) 11(7) 11
Ex
pe
rt 
O
pi
n.
 D
ru
g 
M
et
ab
. T
ox
ic
ol
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
K
 U
 L
eu
ve
n 
on
 0
5/
11
/1
5
Fo
r p
er
so
na
l u
se
 o
nl
y.
maturation: part I-extrapolation of a
covariate model from morphine to
zidovudine. CPT Pharmacometrics
Syst Pharmacol 2012;1:e9
76. European Medicines Agency. 5-year
Report to the European Commission,
General report on the experience
acquired as a result of the application of
the Paediatric Regulation.
2012. EMA/428172/2012 Available
from: http://ec.europa.eu/health/files/
paediatrics/2012-09_pediatric_report-
annex1-2_en.pdf [last accessed
28 January 2015]
77. FDA. Neonatology Subcommittee of the
Pediatric Advisory Committee Meeting.
15 March 2013. Available from: http://
www.fda.gov/downloads/
AdvisoryCommittees/
CommitteesMeetingMaterials/
PediatricAdvisoryCommittee/
UCM342926.pdf [last accessed
28 January 2015]
78. Olski TM, Lampus SF, Gjerarducci G,
Saint Raymond A. Three years of
paediatric regulation in the European
Union. Eur J Clin Pharmacol
2011;67:245--52
79. Carleer J, Karres J. Juvenile animal
studies and paediatric drug development:
a European regulator experience.
Birth Defects Res B Dev Reprod Toxicol
2011;92:254--60
80. Bax R, Tomasi P. Neonatal
pharmacotherapy: legal and regulatory
issues: 108-123. In: Mimouni FB,
van den Anker JN, Editors Pediatric and
Adolescent Medicine, volume 18:
Neonatal pharmacology and nutrition
update. Karger; Basel: 2015
81. Turner MA. Clinical trials of medicines
in neonates: the influence of ethical and
practical issues on design and conduct.
Br J Clin Pharmacol 2015;79(3):370--8
82. Sosenko IR, Bancalari E. NO for
preterm infants at risk for
bronchopulmonary dysplasia. Lancet
2010;376:308--10
83. Ruggieri L, Giannuzzi V, Baiardi P, et al.
Successful private-public funding of
paediatric medicines research: lessons
from the EU programme to fund
research into off-patent medicines.
Eur J Pediatr 2014;174(4):481--91
84. Jacqz-Aigrain E. Drug policy in Europe
Research and funding in neonates:
current challenges, future perspectives,
new opportunities. Early Hum Dev
2011;87(Suppl 1):S27--30
85. Reed MD. Reversing the myths
obstructing the determination of optimal
age- and disease-based drug dosing in
pediatrics. J Pediatr Pharmacol Ther
2011;16:4--13
86. Available from: http://www.fda.gov/
AdvisoryCommittees/Calendar/
ucm341119.htm [last accessed
28 January 2015]
87. De Boeck K, Bulteel V, Tiddens H,
et al. Guideline on the design and
conduct of cystic fibrosis clinical trials:
the European Cystic Fibrosis Society-
Clinical Trials Network (ECFS-CTN).
J Cyst Fibros 2011;10(Suppl 2):S67--74
88. Ruperto N, Martini A. Networking in
paediatrics: the example of Paediatric
Rheumatology International Trials
Organisation (PRINTO). Arch Dis Child
2011;96:596--601
89. Rose AC, van’t Hoff W, Beresford MW,
et al. NIHR Medicines for Children
Research Network: improving children’s
health through clinical research.
Expert Rev Clin Pharmacol
2013;6:581--7
90. Van’t Hoff W, Offringa M. StaR Child
Health: developing evidence-based
guidance for the design, conduct and
reporting of paediatric trials.
Arch Dis Child 2015;100(2):189--92
91. European Medicines Agency. Concept
paper on extrapolation of efficacy and
safety in medicine development Draft.
2012. Available from: http://www.ema.
europa.eu/docs/en_GB/document_library/
Scientific_guideline/2012/06/
WC500129285.pdf [Last accessed
January 2015]
92. Cools F, Askie LM, Offringa M, et al.
Elective high-frequency oscillatory versus
conventional ventilation in preterm
infants: a systematic review and meta-
analysis of individual patients’ data.
Lancet 2010;375:2082--91
93. Askie LM, Ballard RA, Cutter GR, et al.
Inhaled nitric oxide in preterm infants:
an individual-patient data meta-analysis
of randomized trials. Pediatrics
2011;128:729--39
94. Zhao W, Kaguelidou F, Biran V, et al.
External evaluation of population
pharmacokinetic models of vancomycin
in neonates: the transferability of
published models to different clinical
settings. Br J Clin Pharmacol
2013;75:1068--80
. Illustration of the limitations of
extrapolation of a given vancomycin
PK model to another setting
in neonates.
95. Desfrere L, Zohar S, Morville P, et al.
Dose-finding study of ibuprofen in
patent ductus arteriosus using the
continual reassessment method.
J Clin Pharm Ther 2005;30:121--32
96. Thall PF, Nguyen HQ, Zohar S, et al.
Optimizing sedative dose in preterm
infants undergoing treatment for
respiratory distress syndrome.
J Am Stat Assoc 2014;109:931--43
Affiliation
Janko Samardzic1, Mark A Turner2,
Ralph Bax3 & Karel Allegaert†4,5 MD PhD
†Author for correspondence
1University of Belgrade, Institute of
Pharmacology, Clinical Pharmacology and
Toxicology, Medical Faculty, Serbia, Belgrade,
UK
2University of Liverpool, Institute of
Translational Medicine, Department of Women’s
and Children’s Health, Liverpool, UK
3Paediatric Medicines, Product Development
Scientific Support Department, European
Medicines Agency, London, UK
4University Hospitals Leuven, Neonatal Intensive
Care Unit, Herestraat 49, 3000 Leuven, Belgium
Tel: +32 16 343850;
Fax: +32 16 343209;
E-mail: karel.allegaert@uz.kuleuven.ac.be
5Department of Development and Regeneration,
KU Leuven, Belgium
J. Samardzic et al.
12 Expert Opin. Drug Metab. Toxicol. (2015) 11 (7)
Ex
pe
rt 
O
pi
n.
 D
ru
g 
M
et
ab
. T
ox
ic
ol
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
K
 U
 L
eu
ve
n 
on
 0
5/
11
/1
5
Fo
r p
er
so
na
l u
se
 o
nl
y.
